Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Itzhar, Nathalie ^a,b,c   Dessen, Philippe ^a,b   Toujani, Saloua ^a,b   Auger, Nathalie ^a,b,c   Preudhomme, Claude ^d   Richon, Catherine ^a   Lazar, Vladimir ^a,c   Saada, Véronique ^a,c   Bennaceur, Anelyse ^a,c   Bourhis, Jean Henri ^a   de Botton, Stéphane ^a   Bernheim, Alain ^a,b,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Molecular Pathology   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR RUNX1; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 12P; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 18; CHROMOSOME 1Q; CHROMOSOME 21Q; CHROMOSOME 3P; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 7P; CHROMOSOME 7Q; CHROMOSOME 8Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME STRUCTURE; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE IDENTIFICATION; HUMAN; HUMAN CELL; KARYOTYPING; LEUKEMIA; LEUKEMOGENESIS; MALE; MINIMAL CRITICAL REGION; THERAPY RELATED LEUKEMIA; CELL CULTURE; CHEMICALLY INDUCED DISORDER; CHROMOSOME ABERRATION; COMPARATIVE STUDY; GENE DOSAGE; GENETICS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SECOND CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DOSAGE; HUMANS; KARYOTYPING; LEUKEMIA; LEUKEMIA, RADIATION-INDUCED; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; YOUNG ADULT;

EID: 79951875444     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016623     Document Type: Article

References (77)

1. Godley LA, Larson RA, (2008) Therapy-related myeloid leukemia. Semin Oncol 35: 418-429.
2. Leone G, Pagano L, Ben-Yehuda D, Voso MT, (2007) Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92: 1389-1398.
3. Pedersen-Bjergaard J, Andersen MT, Andersen MK, (2007) Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program pp. 392-397.
4. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH, (2008) Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 22: 240-248.
5. Toujani S, Dessen P, Ithzar N, Danglot G, Richon C, et al. (2009) High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. PLoS One 4: e7089.
6. Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, et al. (2009) The UCSC Cancer Genomics Browser. Nat Methods 6: 239-240.
7. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, et al. (2004) Detection of large-scale variation in the human genome. Nat Genet 36: 949-951.
8. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, et al. (2006) Global variation in copy number in the human genome. Nature 444: 444-454.
9. Wong KK, deLeeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, et al. (2007) A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet 80: 91-104.
10. Skjelbred CF, Saebo M, Hjartaker A, Grotmol T, Hansteen IL, et al. (2007) Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas. BMC Cancer 7: 228.
11. Suzen HS, Guvenc G, Turanli M, Comert E, Duydu Y, et al. (2007) The role of GSTM1 and GSTT1 polymorphisms in head and neck cancer risk. Oncol Res 16: 423-429.
12. Sreeja L, Syamala V, Hariharan S, Syamala VS, Raveendran PB, et al. (2008) Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients. J Exp Ther Oncol 7: 73-85.
13. Lin C-H, Li L-H, Ho S-F, Chuang T-P, Wu J-Y, et al. (2008) A large-scale survey of genetic copy number variations among Han Chinese residing in Taiwan. BMC Genetics 9: 92.
14. Schmetzer HM, Braun S, Wiesner D, Duell T, Gerhartz HH, et al. (2000) Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia. Acta Haematol 103: 125-134.
15. Roumier C, Eclache V, Imbert M, Davi F, MacIntyre E, et al. (2003) M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 101: 1277-1283.
16. Dupret C, Asnafi V, Leboeuf D, Millien C, Ben Abdelali R, et al. (2005) IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner. Leukemia 19: 2337-2338.
17. Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, et al. (2002) Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 35: 20-29.
18. Parkin B, Erba H, Ouillette P, Roulston D, Purkayastha A, et al. (2010) Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood.
19. Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, et al. (2010) NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res 16: 4135-4147.
20. Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, et al. (2009) Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 106: 12950-12955.
21. Mrozek K, (2008) Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 35: 365-377.
22. Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, et al. (2007) Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood 110: 799-805.
23. Chen CZ, Li L, Lodish HF, Bartel DP, (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83-86.
24. Karp X, Ambros V, (2005) Developmental biology. Encountering microRNAs in cell fate signaling. Science 310: 1288-1289.
25. Calin GA, Croce CM, (2006) MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 25: 6202-6210.
26. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM, (2006) MicroRNA expression and function in cancer. Trends Mol Med 12: 580-587.
27. Dixon-McIver A, East P, Mein CA, Cazier JB, Molloy G, et al. (2008) Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 3: e2141.
28. Paulsson K, Heidenblad M, Strombeck B, Staaf J, Jonsson G, et al. (2006) High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia 20: 840-846.
29. Rucker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, et al. (2006) Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 24: 3887-3894.
30. Suela J, Alvarez S, Cigudosa JC, (2007) DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res 118: 304-309.
31. Tyybakinoja A, Elonen E, Piippo K, Porkka K, Knuutila S, (2007) Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia 21: 571-574.
32. Akagi T, Ogawa S, Dugas M, Kawamata N, Yamamoto G, et al. (2009) Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 94: 213-223.
33. Akagi T, Shih LY, Kato M, Kawamata N, Yamamoto G, et al. (2009) Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 113: 1741-1748.
34. Akagi T, Shih LY, Ogawa S, Gerss J, Moore SR, et al. (2009) Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells. Haematologica 94: 1301-1306.
35. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, et al. (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 101: 6062-6067.
36. Monnier J, Samson M, (2008) Cytokine properties of prokineticins. FEBS J 275: 4014-4021.
37. Grozdanov PN, Roy S, Kittur N, Meier UT, (2009) SHQ1 is required prior to NAF1 for assembly of H/ACA small nucleolar and telomerase RNPs. RNA 15: 1188-1197.
38. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, et al. (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289-2301.
39. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, et al. (2009) Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 7: 511-522.
40. Stockwin LH, Vistica DT, Kenney S, Schrump DS, Butcher DO, et al. (2009) Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer 9: 22.
41. Evers C, Beier M, Poelitz A, Hildebrandt B, Servan K, et al. (2007) Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes Cancer 46: 1119-1128.
42. Gao M, Liu Q, Zhang F, Han Z, Gu T, et al. (2009) Conserved expression of the PRELI domain containing 2 gene (Prelid2) during mid-later-gestation mouse embryogenesis. J Mol Histol 40: 227-233.
43. Tahvanainen J, Kallonen T, Lahteenmaki H, Heiskanen KM, Westermarck J, et al. (2009) PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation. Blood 113: 1268-1277.
44. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, et al. (2009) Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114: 2733-2743.
45. Fortier JM, Payton JE, Cahan P, Ley TJ, Walter MJ, et al. (2010) POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature. Leukemia 24: 950-957.
46. Niu C, Zhang J, Breslin P, Onciu M, Ma Z, et al. (2009) c-Myc is a target of RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development. Blood 114: 2087-2096.
47. Staudt LM, (2010) Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2: a000109.
48. Ferch U, Kloo B, Gewies A, Pfander V, Duwel M, et al. (2009) Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 206: 2313-2320.
49. Huret JL, (2010) Atlas Genet Cytogenet Oncol Haematol.
50. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537.
51. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, et al. (2002) Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 99: 121-129.
52. Eklund EA, (2007) The role of HOX genes in malignant myeloid disease. Curr Opin Hematol 14: 85-89.
53. Sauvageau G, Lansdorp PM, Eaves CJ, Hogge DE, Dragowska WH, et al. (1994) Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc Natl Acad Sci U S A 91: 12223-12227.
54. Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE, (1999) Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 13: 687-698.
55. Quentmeier H, Dirks WG, Macleod RA, Reinhardt J, Zaborski M, et al. (2004) Expression of HOX genes in acute leukemia cell lines with and without MLL\ translocations. Leuk Lymphoma\ 45\: 567-574\.
56. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, et al. (2010) Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3: ra29.
57. Yamazaki T, Sasaki N, Nishi M, Yamazaki D, Ikeda A, et al. (2007) Augmentation of drug-induced cell death by ER protein BRI3BP. Biochem Biophys Res Commun 362: 971-975.
58. Murr R, Loizou JI, Yang YG, Cuenin C, Li H, et al. (2006) Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat Cell Biol 8: 91-99.
59. Panagopoulos I, Storlazzi CT, Fletcher CD, Fletcher JA, Nascimento A, et al. (2004) The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer 40: 218-228.
60. Lui WO, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, et al. (2008) CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res 68: 7156-7164.
61. Sabri S, Foudi A, Boukour S, Franc B, Charrier S, et al. (2006) Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood 108: 134-140.
62. Farra C, Awwad J, Valent A, Lozach F, Bernheim A, (2004) Complex translocation (8;12;21): a new variant of t(8;21) in acute myeloid leukemia. Cancer Genet Cytogenet 155: 138-142.
63. Storlazzi CT, Fioretos T, Surace C, Lonoce A, Mastrorilli A, et al. (2006) MYC-containing double minutes in hematologic malignancies: evidence in favor of\ the episome model and exclusion of MYC as the target gene. Hum Mol Genet\ 15\: 933-942\.
64. Liu W, Seto J, Sibille E, Toth M, (2003) The RNA binding domain of Jerky consists of tandemly arranged helix-turn-helix/homeodomain-like motifs and binds specific sets of mRNAs. Mol Cell Biol 23: 4083-4093.
65. Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, et al. (2004) Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 103: 4243-4250.
66. Ding Y, Harada Y, Imagawa J, Kimura A, Harada H, (2009) AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 114: 5201-5205.
67. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T, (2003) Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 101: 673-680.
68. Christiansen DH, Andersen MK, Pedersen-Bjergaard J, (2004) Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 104: 1474-1481.
69. Beri-Dexheimer M, Latger-Cannard V, Philippe C, Bonnet C, Chambon P, et al. (2008) Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. Eur J Hum Genet 16: 1014-1018.
70. Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, et al. (2009) High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113: 5583-5587.
71. Baldus CD, Bullinger L, (2008) Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia. Semin Oncol 35: 356-364.
72. Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, et al. (2008) Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chromosomes Cancer 47: 810-818.
73. Clark JP, Cooper CS, (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6: 429-439.
74. Janknecht R, (2005) EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 363: 1-14.
75. Salek-Ardakani S, Smooha G, de Boer J, Sebire NJ, Morrow M, et al. (2009) ERG is a megakaryocytic oncogene. Cancer Res 69: 4665-4673.
76. Stankiewicz MJ, Crispino JD, (2009) ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood 113: 3337-3347.
77. Santoro A, Maggio A, Carbone P, Mirto S, Caronia F, et al. (1992) Amplification of ETS2 oncogene in acute nonlymphoblastic leukemia with t(6;21;18). Cancer Genet Cytogenet 58: 71-75.